Genelux (GNLX) Liabilities and Shareholders Equity (2022 - 2026)
Genelux (GNLX) posted quarterly Liabilities and Shareholders Equity of $32.4 million for Q1 2026, up 70.14% quarter-over-quarter from $19.0 million in Q4 2025.
Genelux (GNLX) Liabilities and Shareholders Equity (2022 - 2026) Analysis & Trends
Genelux's Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $32.4 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $32.4 million; the TTM figure through Mar 2026 stood at $108.6 million (down 9.6% YoY), while the FY2025 annual figure was $19.0 million, down 45.19% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $32.4 million, up from $19.0 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $45.2 million in Q2 2024, with the low at $5.5 million in Q4 2022.
- The 5-year median for Liabilities and Shareholders Equity is $32.2 million (2025), against an average of $29.2 million.
- The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity surged 404.3% in 2023, then slumped 45.19% in 2025.
- Genelux's Liabilities and Shareholders Equity stood at $5.5 million in 2022, then soared by 404.3% to $27.9 million in 2023, then grew by 24.46% to $34.7 million in 2024, then slumped by 45.19% to $19.0 million in 2025, then jumped by 70.14% to $32.4 million in 2026.
- Business Quant data shows GNLX's Liabilities and Shareholders Equity at $32.4 million in Q1 2026, $19.0 million in Q4 2025, and $25.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Genelux | 119.87 Mn | 119.87 Mn | - | 32.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.37 Mn |
| Dec 31, 2025 | 19.03 Mn |
| Sep 30, 2025 | 24.99 Mn |
| Jun 30, 2025 | 32.25 Mn |
| Dec 31, 2024 | 34.72 Mn |
| Sep 30, 2024 | 40.27 Mn |
| Jun 30, 2024 | 45.18 Mn |
| Mar 31, 2024 | 24.68 Mn |
| Dec 31, 2023 | 27.89 Mn |
| Sep 30, 2023 | 34.07 Mn |
| Dec 31, 2022 | 5.53 Mn |